People who take the obesity medication Wegovy for at least four years retain significant weight loss and experience fewer serious adverse effects than those who receive a placebo (or “dummy”) treatment, according to the largest and longest-running study on the drug.
Physicians predict that the discovery will put more pressure on UK health authorities, who presently only allow two years of treatment.
After four years, they had reduced their waist size by 7.7cm and lost 10.2% of their body weight on average.
Results showed that people with mild obesity or those who dropped only little amounts of weight saw significant cardiovascular improvements.
